Multivalent Targeting of the Asialoglycoprotein Receptor by Virus-Like Particles

被引:4
|
作者
Hincapie, Robert [1 ]
Bhattacharya, Sonia [1 ]
Baksh, Michael M. [1 ]
Sanhueza, Carlos A. [1 ]
Echeverri, Elisa Schrader [2 ,3 ]
Kim, Hyejin [2 ,3 ]
Paunovska, Kalina [2 ,3 ]
Podilapu, Ananda R. [1 ]
Xu, Minghao [1 ]
Dahlman, James E. [2 ,3 ]
Finn, M. G. [1 ,4 ]
机构
[1] Georgia Inst Technol, Sch Chem & Biochem, 901 Atlantic Dr, Atlanta, GA 30332 USA
[2] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr NW, Atlanta, GA 30332 USA
[3] Emory Sch Med, 313 Ferst Dr NW, Atlanta, GA 30332 USA
[4] Georgia Inst Technol, Sch Biol Sci, 901 Atlantic Dr, Atlanta, GA 30332 USA
关键词
hepatocellular targeting; nanoparticles; protein-carbohydrate conjugates; virus-like particles; IN-VIVO; HIGH-AFFINITY; MOSAIC-VIRUS; GENE-THERAPY; CELL; NANOPARTICLE; HEPATOCYTES; DELIVERY; LIGANDS; BINDING;
D O I
10.1002/smll.202304263
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The asialoglycoprotein receptor (ASGPR) is expressed in high density on hepatocytes. Multivalent variants of galactosyl carbohydrates bind ASGPR with high affinity, enabling hepatic delivery of ligand-bound cargo. Virus-like particle (VLP) conjugates of a relatively high-affinity ligand were efficiently endocytosed by ASGPR-expressing cells in a manner strongly dependent on the nature and density of ligand display, with the best formulation using a nanomolar-, but not a picomolar-level, binder. Optimized particles were taken up by HepG2 cells with greater efficiency than competing small molecules or the natural multigalactosylated ligand, asialoorosomucoid. Upon systemic injection in mice, these VLPs were rapidly cleared to the liver and were found in association with sinusoidal endothelial cells, Kupffer cells, hepatocytes, dendritic cells, and other immune cells. Both ASGPR-targeted and nontargeted particles were distributed similarly to endothelial and Kupffer cells, but targeted particles were distributed to a greater number and fraction of hepatocytes. Thus, selective cellular trafficking in the liver is difficult to achieve: even with the most potent ASGPR targeting available, barrier cells take up much of the injected particles and hepatocytes are accessed only approximately twice as efficiently in the best case. Delivery of drugs to particular cell types in the liver is a useful goal. Heptatocytes are typically targeted using molecules that bind to the asialoglycoprotein receptor. This paper describes the construction of protein nanoparticles with ultra-high affinity for cells bearing this receptor, while showing that uptake by other liver cells is difficult to overcome if hepatocyte-specific delivery is desired.image
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Multivalent Targeting of the Asialoglycoprotein Receptor by Virus-Like Particles
    Hincapie, Robert
    Bhattacharya, Sonia
    Baksh, Michael M.
    Sanhueza, Carlos A.
    Echeverri, Elisa Schrader
    Kim, Hyejin
    Paunovska, Kalina
    Podilapu, Ananda R.
    Xu, Minghao
    Dahlman, James E.
    Finn, M. G.
    SMALL, 2023,
  • [2] Cell Targeting with Hybrid Qβ Virus-Like Particles Displaying Epidermal Growth Factor
    Pokorski, Jonathan K.
    Hovlid, Marisa L.
    Finn, M. G.
    CHEMBIOCHEM, 2011, 12 (16) : 2441 - 2447
  • [3] Virus-like Particles for Disease Diagnosis and Drug Delivery Applications
    Sharma, Rishav
    Malviya, Rishabha
    CURRENT NANOSCIENCE, 2024, 20 (05) : 613 - 629
  • [4] The Role of Virus-Like Particles in Medical Biotechnology
    Comas-Garcia, Mauricio
    Colunga-Saucedo, Mayra
    Rosales-Mendoza, Sergio
    MOLECULAR PHARMACEUTICS, 2020, 17 (12) : 4407 - 4420
  • [5] Virus-like particles: a self-assembled toolbox for cancer therapy
    Shahrivarkevishahi, A.
    Hagge, L. M.
    Brohlin, O. R.
    Kumari, S.
    Ehrman, R.
    Benjamin, C.
    Gassensmith, J. J.
    MATERIALS TODAY CHEMISTRY, 2022, 24
  • [6] Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
    Tornesello, Anna Lucia
    Tagliamonte, Maria
    Buonaguro, Franco M.
    Tornesello, Maria Lina
    Buonaguro, Luigi
    VACCINES, 2022, 10 (02)
  • [7] Virus-Like Particles as Theranostic Platforms
    Sun, Xianxun
    Cui, Zongqiang
    ADVANCED THERAPEUTICS, 2020, 3 (05)
  • [8] Virus-like particles as vaccine
    Chroboczek, Jadwiga
    Szurgot, Inga
    Szolajska, Ewa
    ACTA BIOCHIMICA POLONICA, 2014, 61 (03) : 531 - 539
  • [9] Virus-Like Particles as an Instrument of Vaccine Production
    Syomin, B. V.
    Ilyin, Y. V.
    MOLECULAR BIOLOGY, 2019, 53 (03) : 323 - 334
  • [10] Virus-like particles for vaccination against cancer
    Mohsen, Mona O.
    Speiser, Daniel E.
    Knuth, Alexander
    Bachmann, Martin F.
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2020, 12 (01)